Physician profile
Danny Chu
NPI 1891886842
$292,889.75
in general payments reported to CMS, 2019-2025
22 companies · $78K in 2025
The $78K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $17K · 2021: $23K · 2022: $30K · 2023: $28K · 2024: $38K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Food and Beverage: $8,346 · Consulting Fee: $4,860 · Travel and Lodging: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,491.00 |
| Food and Beverage | $8,346.35 |
| Consulting Fee | $4,860.00 |
| Travel and Lodging | $2,171.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $218,816.70 | 2019-2025 | Vemlidy, Epclusa |
| Madrigal Pharmaceuticals | $72,158.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $472.70 | 2020-2025 | |
| Fujifilm Healthcare Americas Corporation | $254.99 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $189.44 | 2024-2025 | Voquezna |
| Pfizer INC. | $180.82 | 2019-2023 | |
| Sirtex Medical INC | $134.49 | 2023 | Sir-Spheres Microspheres |
| Allergan, INC. | $132.42 | 2019 | |
| Romark Laboratories, Lc | $129.11 | 2019 | |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Janssen Biotech, INC. | $51.78 | 2025 | Tremfya |
| Abbott Laboratories | $48.76 | 2025 | Epic |
| Nestle Healthcare Nutrition INC. | $36.64 | 2021-2022 | |
| Ardelyx, INC. | $29.07 | 2025 | Ibsrela |
| Celgene Corporation | $28.83 | 2024 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $26.25 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.18 | 2025 | Xifaxan |
| Hikma Pharmaceuticals USA | $16.97 | 2022 | |
| Intra-Sana Laboratories | $16.02 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Concordia Pharmaceuticals INC. | $13.18 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $12.92 | 2024 | Sureclip |
| Lilly USA, LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.